Abstract
Background: Trials of multiple amyloid‐reducing antibodies have demonstrated slowing of Alzheimer’s disease (AD) progression by 25‐30% with optimal treatment, confirming the validity of the amyloid therapeutic hypothesis. These antibodies target fibrillar and, in some cases, pre‐fibrillar forms of aggregated amyloid. BACE (β‐site amyloid precursor protein cleaving enzyme) inhibitors block generation of the amyloid peptide, reducing smaller diffusible species that may contribute to amyloid toxicity. BACE inhibition may therefore complement immunotherapy.Method: Based on the results of trials with amyloid‐removing antibodies and various BACE inhibitors, trials can be envisioned to explore the therapeutic values of inhibiting amyloid peptide generation.Result: Since multiple forms of amyloid are neurotoxic, the beneficial effects of BACE inhibition alone, in sequence or in combination with amyloid‐reducing antibodies should be tested in trials. BACE inhibitors are ideal candidates for primary prevention trials, with high‐risk amyloid‐PET negative individuals identified using plasma biomarkers (amyloid β peptide and ptau ratios); the impact of therapy may be assessed with effect on plasma ptau species as the primary biomarker endpoint. In individuals with positive amyloid PET scans, whether asymptomatic or with early AD, BACE inhibition should be tested in combination with or following effective amyloid removal with immunotherapy; cognitive and clinical outcome measures are appropriate in these populations. Dosing should target 25‐50% inhibition of BACE, with monitoring of cognition to facilitate dose adjustment when necessary. Clinical trial designs will be presented.Conclusion: BACE inhibitor therapy to reduce the generation of amyloid peptides offers an opportunity to build on the success of amyloid‐removing antibodies in the treatment and prevention of Alzheimer’s disease.